 | • レポートコード：MRC2-11QY01113 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は血友病薬のグローバル市場について調査・分析したレポートです。種類別（血友病A、阻害剤、血友病B、フォンウィルブランド病）市場規模、用途別（組換え療法、血漿由来療法）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別血友病薬の競争状況、市場シェア ・世界の血友病薬市場：種類別市場規模 2015年-2020年（血友病A、阻害剤、血友病B、フォンウィルブランド病） ・世界の血友病薬市場：種類別市場規模予測 2021年-2026年（血友病A、阻害剤、血友病B、フォンウィルブランド病） ・世界の血友病薬市場：用途別市場規模 2015年-2020年（組換え療法、血漿由来療法） ・世界の血友病薬市場：用途別市場規模予測 2021年-2026年（組換え療法、血漿由来療法） ・北米の血友病薬市場分析：米国、カナダ ・ヨーロッパの血友病薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの血友病薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の血友病薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの血友病薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Baxalta、Bayer、CSL Behring、Pfizer、Alnylam Pharmaceuticals、BioMarin、Catalyst Biosciences、Dimension Therapeutics、F. Hoffmann-La Roche、Grifols、Octapharma、Sangamo Biosciences、Spark Therapeutics、Swedish Orphan Biovitrum ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
Market Analysis and Insights: Global Hemophilia Drugs Market
The global Hemophilia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hemophilia Drugs Scope and Market Size
Hemophilia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hemophilia Drugs market is segmented into
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
Segment by Application, the Hemophilia Drugs market is segmented into
Recombinant Therapies
Plasma-Derived Therapies
Regional and Country-level Analysis
The Hemophilia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hemophilia Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hemophilia Drugs Market Share Analysis
Hemophilia Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hemophilia Drugs business, the date to enter into the Hemophilia Drugs market, Hemophilia Drugs product introduction, recent developments, etc.
The major vendors covered:
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
1 Study Coverage
1.1 Hemophilia Drugs Product Introduction
1.2 Market Segments
1.3 Key Hemophilia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hemophilia Drugs Market Size Growth Rate by Type
1.4.2 Hemophilia A
1.4.3 Inhibitors
1.4.4 Hemophilia B
1.4.5 Von Willebrand Disease
1.5 Market by Application
1.5.1 Global Hemophilia Drugs Market Size Growth Rate by Application
1.5.2 Recombinant Therapies
1.5.3 Plasma-Derived Therapies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hemophilia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hemophilia Drugs Revenue 2015-2026
2.1.2 Global Hemophilia Drugs Sales 2015-2026
2.2 Global Hemophilia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hemophilia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hemophilia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hemophilia Drugs Competitor Landscape by Players
3.1 Hemophilia Drugs Sales by Manufacturers
3.1.1 Hemophilia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hemophilia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hemophilia Drugs Revenue by Manufacturers
3.2.1 Hemophilia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hemophilia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hemophilia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hemophilia Drugs Revenue in 2019
3.2.5 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hemophilia Drugs Price by Manufacturers
3.4 Hemophilia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hemophilia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hemophilia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hemophilia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hemophilia Drugs Market Size by Type (2015-2020)
4.1.1 Global Hemophilia Drugs Sales by Type (2015-2020)
4.1.2 Global Hemophilia Drugs Revenue by Type (2015-2020)
4.1.3 Hemophilia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hemophilia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hemophilia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hemophilia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hemophilia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hemophilia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hemophilia Drugs Market Size by Application (2015-2020)
5.1.1 Global Hemophilia Drugs Sales by Application (2015-2020)
5.1.2 Global Hemophilia Drugs Revenue by Application (2015-2020)
5.1.3 Hemophilia Drugs Price by Application (2015-2020)
5.2 Hemophilia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hemophilia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hemophilia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hemophilia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hemophilia Drugs by Country
6.1.1 North America Hemophilia Drugs Sales by Country
6.1.2 North America Hemophilia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hemophilia Drugs Market Facts & Figures by Type
6.3 North America Hemophilia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hemophilia Drugs by Country
7.1.1 Europe Hemophilia Drugs Sales by Country
7.1.2 Europe Hemophilia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hemophilia Drugs Market Facts & Figures by Type
7.3 Europe Hemophilia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hemophilia Drugs by Region
8.1.1 Asia Pacific Hemophilia Drugs Sales by Region
8.1.2 Asia Pacific Hemophilia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hemophilia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hemophilia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hemophilia Drugs by Country
9.1.1 Latin America Hemophilia Drugs Sales by Country
9.1.2 Latin America Hemophilia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hemophilia Drugs Market Facts & Figures by Type
9.3 Central & South America Hemophilia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hemophilia Drugs by Country
10.1.1 Middle East and Africa Hemophilia Drugs Sales by Country
10.1.2 Middle East and Africa Hemophilia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Baxalta
11.1.1 Baxalta Corporation Information
11.1.2 Baxalta Description and Business Overview
11.1.3 Baxalta Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxalta Hemophilia Drugs Products Offered
11.1.5 Baxalta Related Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Description and Business Overview
11.2.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bayer Hemophilia Drugs Products Offered
11.2.5 Bayer Related Developments
11.3 CSL Behring
11.3.1 CSL Behring Corporation Information
11.3.2 CSL Behring Description and Business Overview
11.3.3 CSL Behring Sales, Revenue and Gross Margin (2015-2020)
11.3.4 CSL Behring Hemophilia Drugs Products Offered
11.3.5 CSL Behring Related Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Description and Business Overview
11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer Hemophilia Drugs Products Offered
11.4.5 Pfizer Related Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Corporation Information
11.5.2 Alnylam Pharmaceuticals Description and Business Overview
11.5.3 Alnylam Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Alnylam Pharmaceuticals Hemophilia Drugs Products Offered
11.5.5 Alnylam Pharmaceuticals Related Developments
11.6 BioMarin
11.6.1 BioMarin Corporation Information
11.6.2 BioMarin Description and Business Overview
11.6.3 BioMarin Sales, Revenue and Gross Margin (2015-2020)
11.6.4 BioMarin Hemophilia Drugs Products Offered
11.6.5 BioMarin Related Developments
11.7 Catalyst Biosciences
11.7.1 Catalyst Biosciences Corporation Information
11.7.2 Catalyst Biosciences Description and Business Overview
11.7.3 Catalyst Biosciences Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Catalyst Biosciences Hemophilia Drugs Products Offered
11.7.5 Catalyst Biosciences Related Developments
11.8 Dimension Therapeutics
11.8.1 Dimension Therapeutics Corporation Information
11.8.2 Dimension Therapeutics Description and Business Overview
11.8.3 Dimension Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Dimension Therapeutics Hemophilia Drugs Products Offered
11.8.5 Dimension Therapeutics Related Developments
11.9 F. Hoffmann-La Roche
11.9.1 F. Hoffmann-La Roche Corporation Information
11.9.2 F. Hoffmann-La Roche Description and Business Overview
11.9.3 F. Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.9.4 F. Hoffmann-La Roche Hemophilia Drugs Products Offered
11.9.5 F. Hoffmann-La Roche Related Developments
11.10 Grifols
11.10.1 Grifols Corporation Information
11.10.2 Grifols Description and Business Overview
11.10.3 Grifols Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Grifols Hemophilia Drugs Products Offered
11.10.5 Grifols Related Developments
11.1 Baxalta
11.1.1 Baxalta Corporation Information
11.1.2 Baxalta Description and Business Overview
11.1.3 Baxalta Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxalta Hemophilia Drugs Products Offered
11.1.5 Baxalta Related Developments
11.12 Sangamo Biosciences
11.12.1 Sangamo Biosciences Corporation Information
11.12.2 Sangamo Biosciences Description and Business Overview
11.12.3 Sangamo Biosciences Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sangamo Biosciences Products Offered
11.12.5 Sangamo Biosciences Related Developments
11.13 Spark Therapeutics
11.13.1 Spark Therapeutics Corporation Information
11.13.2 Spark Therapeutics Description and Business Overview
11.13.3 Spark Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Spark Therapeutics Products Offered
11.13.5 Spark Therapeutics Related Developments
11.14 Swedish Orphan Biovitrum
11.14.1 Swedish Orphan Biovitrum Corporation Information
11.14.2 Swedish Orphan Biovitrum Description and Business Overview
11.14.3 Swedish Orphan Biovitrum Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Swedish Orphan Biovitrum Products Offered
11.14.5 Swedish Orphan Biovitrum Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hemophilia Drugs Market Estimates and Projections by Region
12.1.1 Global Hemophilia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hemophilia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hemophilia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hemophilia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hemophilia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hemophilia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hemophilia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hemophilia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hemophilia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hemophilia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hemophilia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hemophilia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hemophilia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hemophilia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hemophilia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hemophilia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hemophilia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hemophilia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hemophilia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hemophilia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hemophilia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hemophilia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hemophilia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hemophilia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hemophilia Drugs Market Segments
Table 2. Ranking of Global Top Hemophilia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hemophilia Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Hemophilia A
Table 5. Major Manufacturers of Inhibitors
Table 6. Major Manufacturers of Hemophilia B
Table 7. Major Manufacturers of Von Willebrand Disease
Table 8. Global Hemophilia Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 9. Global Hemophilia Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 10. Global Hemophilia Drugs Sales by Regions 2015-2020 (K MT)
Table 11. Global Hemophilia Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Hemophilia Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Hemophilia Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 14. Global Hemophilia Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Hemophilia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia Drugs as of 2019)
Table 17. Hemophilia Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Hemophilia Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Hemophilia Drugs Price (2015-2020) (USD/MT)
Table 20. Hemophilia Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Hemophilia Drugs Product Type
Table 22. Date of International Manufacturers Enter into Hemophilia Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 25. Global Hemophilia Drugs Sales Share by Type (2015-2020)
Table 26. Global Hemophilia Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Hemophilia Drugs Revenue Share by Type (2015-2020)
Table 28. Hemophilia Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 29. Global Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 30. Global Hemophilia Drugs Sales Share by Application (2015-2020)
Table 31. North America Hemophilia Drugs Sales by Country (2015-2020) (K MT)
Table 32. North America Hemophilia Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Hemophilia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Hemophilia Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 36. North America Hemophilia Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 38. North America Hemophilia Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Hemophilia Drugs Sales by Country (2015-2020) (K MT)
Table 40. Europe Hemophilia Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Hemophilia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Hemophilia Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 44. Europe Hemophilia Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 46. Europe Hemophilia Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Hemophilia Drugs Sales by Region (2015-2020) (K MT)
Table 48. Asia Pacific Hemophilia Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Hemophilia Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Hemophilia Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 52. Asia Pacific Hemophilia Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 54. Asia Pacific Hemophilia Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Hemophilia Drugs Sales by Country (2015-2020) (K MT)
Table 56. Latin America Hemophilia Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Hemophilia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Hemophilia Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 60. Latin America Hemophilia Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 62. Latin America Hemophilia Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Hemophilia Drugs Sales by Country (2015-2020) (K MT)
Table 64. Middle East and Africa Hemophilia Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Hemophilia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Hemophilia Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Hemophilia Drugs Sales by Type (2015-2020) (K MT)
Table 68. Middle East and Africa Hemophilia Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Hemophilia Drugs Sales by Application (2015-2020) (K MT)
Table 70. Middle East and Africa Hemophilia Drugs Sales Market Share by Application (2015-2020)
Table 71. Baxalta Corporation Information
Table 72. Baxalta Description and Major Businesses
Table 73. Baxalta Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 74. Baxalta Product
Table 75. Baxalta Recent Development
Table 76. Bayer Corporation Information
Table 77. Bayer Description and Major Businesses
Table 78. Bayer Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. Bayer Product
Table 80. Bayer Recent Development
Table 81. CSL Behring Corporation Information
Table 82. CSL Behring Description and Major Businesses
Table 83. CSL Behring Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. CSL Behring Product
Table 85. CSL Behring Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Alnylam Pharmaceuticals Corporation Information
Table 92. Alnylam Pharmaceuticals Description and Major Businesses
Table 93. Alnylam Pharmaceuticals Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Alnylam Pharmaceuticals Product
Table 95. Alnylam Pharmaceuticals Recent Development
Table 96. BioMarin Corporation Information
Table 97. BioMarin Description and Major Businesses
Table 98. BioMarin Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. BioMarin Product
Table 100. BioMarin Recent Development
Table 101. Catalyst Biosciences Corporation Information
Table 102. Catalyst Biosciences Description and Major Businesses
Table 103. Catalyst Biosciences Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Catalyst Biosciences Product
Table 105. Catalyst Biosciences Recent Development
Table 106. Dimension Therapeutics Corporation Information
Table 107. Dimension Therapeutics Description and Major Businesses
Table 108. Dimension Therapeutics Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Dimension Therapeutics Product
Table 110. Dimension Therapeutics Recent Development
Table 111. F. Hoffmann-La Roche Corporation Information
Table 112. F. Hoffmann-La Roche Description and Major Businesses
Table 113. F. Hoffmann-La Roche Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. F. Hoffmann-La Roche Product
Table 115. F. Hoffmann-La Roche Recent Development
Table 116. Grifols Corporation Information
Table 117. Grifols Description and Major Businesses
Table 118. Grifols Hemophilia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. Grifols Product
Table 120. Grifols Recent Development
Table 121. Octapharma Corporation Information
Table 122. Octapharma Description and Major Businesses
Table 123. Octapharma Hemophilia Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 124. Octapharma Product
Table 125. Octapharma Recent Development
Table 126. Sangamo Biosciences Corporation Information
Table 127. Sangamo Biosciences Description and Major Businesses
Table 128. Sangamo Biosciences Hemophilia Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 129. Sangamo Biosciences Product
Table 130. Sangamo Biosciences Recent Development
Table 131. Spark Therapeutics Corporation Information
Table 132. Spark Therapeutics Description and Major Businesses
Table 133. Spark Therapeutics Hemophilia Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 134. Spark Therapeutics Product
Table 135. Spark Therapeutics Recent Development
Table 136. Swedish Orphan Biovitrum Corporation Information
Table 137. Swedish Orphan Biovitrum Description and Major Businesses
Table 138. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 139. Swedish Orphan Biovitrum Product
Table 140. Swedish Orphan Biovitrum Recent Development
Table 141. Global Hemophilia Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 142. Global Hemophilia Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 143. Global Hemophilia Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 144. Global Hemophilia Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 145. North America: Hemophilia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 146. North America: Hemophilia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Europe: Hemophilia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 148. Europe: Hemophilia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Asia Pacific: Hemophilia Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 150. Asia Pacific: Hemophilia Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 151. Latin America: Hemophilia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 152. Latin America: Hemophilia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Middle East and Africa: Hemophilia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 154. Middle East and Africa: Hemophilia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 156. Key Challenges
Table 157. Market Risks
Table 158. Main Points Interviewed from Key Hemophilia Drugs Players
Table 159. Hemophilia Drugs Customers List
Table 160. Hemophilia Drugs Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Hemophilia Drugs Product Picture
Figure 2. Global Hemophilia Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Hemophilia A Product Picture
Figure 4. Inhibitors Product Picture
Figure 5. Hemophilia B Product Picture
Figure 6. Von Willebrand Disease Product Picture
Figure 7. Global Hemophilia Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Recombinant Therapies
Figure 9. Plasma-Derived Therapies
Figure 10. Hemophilia Drugs Report Years Considered
Figure 11. Global Hemophilia Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Hemophilia Drugs Sales 2015-2026 (K MT)
Figure 13. Global Hemophilia Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Hemophilia Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Hemophilia Drugs Sales Market Share by Region in 2019
Figure 16. Global Hemophilia Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Hemophilia Drugs Revenue Market Share by Region in 2019
Figure 18. Global Hemophilia Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Hemophilia Drugs Revenue in 2019
Figure 20. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Hemophilia Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Hemophilia Drugs Sales Market Share by Type in 2019
Figure 23. Global Hemophilia Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Hemophilia Drugs Revenue Market Share by Type in 2019
Figure 25. Global Hemophilia Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Hemophilia Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Hemophilia Drugs Sales Market Share by Application in 2019
Figure 28. Global Hemophilia Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Hemophilia Drugs Revenue Market Share by Application in 2019
Figure 30. North America Hemophilia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 31. North America Hemophilia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Hemophilia Drugs Sales Market Share by Country in 2019
Figure 33. North America Hemophilia Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 35. U.S. Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 37. Canada Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Hemophilia Drugs Market Share by Type in 2019
Figure 39. North America Hemophilia Drugs Market Share by Application in 2019
Figure 40. Europe Hemophilia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 41. Europe Hemophilia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Hemophilia Drugs Sales Market Share by Country in 2019
Figure 43. Europe Hemophilia Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 45. Germany Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 47. France Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 49. U.K. Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 51. Italy Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 53. Russia Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Hemophilia Drugs Market Share by Type in 2019
Figure 55. Europe Hemophilia Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Hemophilia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 57. Asia Pacific Hemophilia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Hemophilia Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Hemophilia Drugs Revenue Market Share by Region in 2019
Figure 60. China Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 61. China Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 63. Japan Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 65. South Korea Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 67. India Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 69. Australia Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 71. Taiwan Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 73. Indonesia Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 75. Thailand Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 77. Malaysia Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 79. Philippines Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 81. Vietnam Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Hemophilia Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Hemophilia Drugs Market Share by Application in 2019
Figure 84. Latin America Hemophilia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 85. Latin America Hemophilia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Hemophilia Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Hemophilia Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 89. Mexico Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 91. Brazil Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 93. Argentina Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Hemophilia Drugs Market Share by Type in 2019
Figure 95. Latin America Hemophilia Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Hemophilia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 97. Middle East and Africa Hemophilia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Hemophilia Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Hemophilia Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 101. Turkey Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 103. Saudi Arabia Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Hemophilia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 105. U.A.E Hemophilia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Hemophilia Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Hemophilia Drugs Market Share by Application in 2019
Figure 108. North America Hemophilia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 109. North America Hemophilia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Hemophilia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 111. Europe Hemophilia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Hemophilia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. Asia Pacific Hemophilia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Hemophilia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Latin America Hemophilia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Hemophilia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. Middle East and Africa Hemophilia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
血友病治療薬の世界市場（～2026年） Hemophilia is a rare disorder in which your blood doesn't clot normally because it lacks sufficient blood-clotting proteins (clotting factors). Market Analysis and Insights: Global Hemophilia Treatment Drugs Market The global Hemophilia Treatment Drugs market size is projected to reach US$ 11160 mil…- 血友病A・B組換え因子補充療法の世界市場（～2026年） Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptom…
- 血友病A治療薬の世界市場（～2026年） Market Analysis and Insights: Global Hemophilia A Drug Market The global Hemophilia A Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hemophilia A Drug Scope and Market Size Hemophilia A Drug market is segmented b…
- 植物・植物由来薬剤の世界市場（～2026年） Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. Botanical drugs consist of vegetable material, algae and macroscopic fungi…
- PEG化医薬品の世界市場（～2026年） Market Analysis and Insights: Global PEGylated Drugs Market The global PEGylated Drugs market size is projected to reach US$ 7218.2 million by 2026, from US$ 7003.6 million in 2020, at a CAGR of 2.8%% during 2021-2026. Global PEGylated Drugs Scope and Market Size PEGylated Drugs market is segmented …